ABSTRACT
Enzymatic removal of blood groups antigens A and B is an efficient method for production of universal red blood cells. In this research, an α-N-acetylgalactosaminidase (NAGA) enzyme was expressed in Pichia pastoris for digestion of the A blood antigen. DNA sequence of the gene NAGA, originally expressed in Elizabethkingia meningosepticum (NAGA-EM), was ordered for optimization and synthesis. It was then expressed in P. pastoris (KM71H and GS115 strains). Expression of the recombinant NAGA was evaluated by dot blot, SDS-PAGE, and Western blotting. The activity of the enzyme was measured using a synthetic substrate in addition to the conversion of group A red blood cells to the O cells. Expression of NAGA-EM with an apparent molecular mass of 55 kDa was verified by dot blot, SDS-PAGE and Western blot analysis. The maximum enzyme activity in the supernatant of KM71H was higher than that in the GS115 (250 vs. 200 U/ml). Treated group A RBCs did not react with the anti-A antiserum or with the sera from individuals with blood groups B and O. The results of this study indicated that NAGA-EM is an efficient enzyme for production of universal O blood cells.
ABSTRACT
INTRODUCTION: While some metals are required for physiological functions in the form of essential trace elements, they can cause toxicity in the excessive concentrations. Chelation therapy was used to reduce the adverse effects of acute and chronic poisoning by metals. Isatin derivatives form complexes with copper ions indicating that they may have protective activity against metal overload. METHOD: In this study, four compounds (isatin and three isatin-derivatives Mj1, TR and Mk1) were evaluated for drug-likeliness. Then their potency inhibiting cell proliferation was determined in HEK293 cell culture assay. Finally, IC50 values for lead, copper, and iron was evaluated in the absence and also the presence of isatin and its derivatives. RESULTS: Isatin and its derivatives used in this study complied with the Lipinski criteria for drug-likeliness. The greatest difference between the IC50 values and the non-toxic dose was obtained for TR and Mj1, respectively. Pretreatment with the Mj1 increased the IC50 values for lead, iron, and copper, by 2.1, 1.7 and 1.7 times, respectively. At non-toxic dose, TR has only increased the IC50 values for lead and copper by 1.4 and 1.3 times without affecting iron cytotoxicity. Mk1 increased the IC50 values for lead, copper, and iron by 1.3, 1.8 and 1.7 times, respectively. CONCLUSIONS: Mj1 is suggested as a lead compound for developing therapeutic agents for lead (Pb) toxicity and Mk1 for copper and iron.
